secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000950170-24-118569
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo announces positive interim Phase 1/2 data for LX1001 gene therapy in APOE4 Alzheimer's
--------------------------------------------------------------------------------

- LX1001 showed dose-dependent APOE2 expression in all participants with durability to 12 months.
- CSF tau biomarkers (T-tau, P-tau181, P-tau217, P-tau231) reduced in >2/3 of participants relative to baseline.
- No reports of ARIA; four SAEs reported, one hearing loss possibly related, repeat audiometry pending.
- Company initiated FDA engagement; expects update on regulatory interactions and development plans in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024118569/0000950170-24-118569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024118569/lxeo-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-118569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer